Cardialysis BV   Report issue

For profit Phase 3
Founded: Rotterdam Netherlands (1983)

Organization Overview

First Clinical Trial
2014
NCT02303717
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Cardialysis B.V.

Active Ingredients

Drugs in Phase 3 Trials (3)

acetylsalicylic acid (aspirin) (3 trials)

clopidogrel (plavix) (3 trials)

rivaroxaban (xarelto) (1 trial)

Drugs in Other Trials (1)

prasugrel (effient) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aortic Valve Stenosis (Phase 3)

Cardiovascular Diseases (Phase 3)

Heart Valve Diseases (Phase 3)

Thrombosis (Phase 3)

Ventricular Outflow Obstruction (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 4